Lisdexamfetamine Dimesylate (LDX)
Lisdexamfetamine Dimesylate (LDX) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
4 of 4 finished
0.0%
0 ended early
0
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
Clinical Trials (4)
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4